Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high costs—often exceeding $1,000 per month—put them out of reach for many Americans whose ...
Each year, millions of Americans file new business applications, but only a fraction of these ventures survive the critical first few years. A new analysis from Simply Business breaks down ...